John Osth
Chief Executive Officer at QuantumCor, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Mitchell R. Stoller | M | - |
The Marrow Foundation
| 17 years |
| Howard J. Kerr | M | 89 |
The Marrow Foundation
| - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Geri Sands Hansen | F | - |
The University of Chicago
| 4 years |
| Todd Eugene Petzel | M | - |
The University of Chicago
| 7 years |
| Brady Dougan | M | 64 |
The University of Chicago
| 5 years |
| Michael Anthony Duffy | M | - |
The University of Chicago
| 8 years |
| Mary Patricia Quinn | F | - |
The University of Chicago
| 5 years |
| Victor Canto | M | - |
The University of Chicago
| 5 years |
| Audrey Lew | F | 59 |
Chemokine Therapeutics Corp.
 Chemokine Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Chemokine Therapeutics Corp. is a biotechnology company, developing chemokine-based therapies to treat cancer, blood disorders and vascular diseases. The company's product candidates in clinical trials include CTCE-0214, for enhancing the immune system; and CTCE-9908, to prevent the spread of cancer and its continued growth. Chemokine Therapeutics was founded on July 15, 1998 and is headquartered in Vancouver, Canada. | 2 years |
| Kevin K. Pfeffer | M | - |
The University of Chicago
| 6 years |
| Mauricio Antonio González Gómez | M | - |
The University of Chicago
| 3 years |
| George K. Hersh | M | - |
The University of Chicago
| 6 years |
| Kai Kuo Chao | M | - |
The University of Chicago
| 3 years |
| Theo Vermaelen | M | 70 |
The University of Chicago
| 6 years |
| Charles Frederick Pohl | M | - |
The University of Chicago
| 5 years |
| Hassan Salari | M | 69 |
Chemokine Therapeutics Corp.
Chemokine Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Chemokine Therapeutics Corp. is a biotechnology company, developing chemokine-based therapies to treat cancer, blood disorders and vascular diseases. The company's product candidates in clinical trials include CTCE-0214, for enhancing the immune system; and CTCE-9908, to prevent the spread of cancer and its continued growth. Chemokine Therapeutics was founded on July 15, 1998 and is headquartered in Vancouver, Canada. | 9 years |
| Dennis Joseph McNamara | M | 70 |
The University of Chicago
| 7 years |
| Bashir Jaffer | M | 76 |
Chemokine Therapeutics Corp.
Chemokine Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Chemokine Therapeutics Corp. is a biotechnology company, developing chemokine-based therapies to treat cancer, blood disorders and vascular diseases. The company's product candidates in clinical trials include CTCE-0214, for enhancing the immune system; and CTCE-9908, to prevent the spread of cancer and its continued growth. Chemokine Therapeutics was founded on July 15, 1998 and is headquartered in Vancouver, Canada. | 2 years |
| Stu J. Sweet | M | - |
The University of Chicago
| 6 years |
| Tibor D. Klopfer | M | - |
The University of Chicago
| 3 years |
| Scott E. Pickens | M | - |
The University of Chicago
| 2 years |
| Steven Shebik | M | 67 |
The University of Chicago
| 2 years |
| David Guilmette | M | 61 |
The University of Chicago
| 4 years |
| David Wagener | M | 69 |
The University of Chicago
| 2 years |
| Mike S. Gilman | M | - |
The University of Chicago
| 2 years |
| Paul Alivisatos | M | - |
The University of Chicago
| 4 years |
| William S. Dorson | M | - |
The University of Chicago
| 2 years |
| Dominic C. Yang | M | - |
The University of Chicago
| 4 years |
| Richard Straube | M | 72 |
The University of Chicago
| 3 years |
| Alice Peters | F | - |
The University of Chicago
| 1 years |
| Preston L. C. Johnson | M | - |
The University of Chicago
| 2 years |
| Ezra Katzen | M | 70 |
The University of Chicago
| 3 years |
| Joseph W. Hill | M | - |
The University of Chicago
| 2 years |
| Robert j. Minkus | M | - |
The University of Chicago
| 3 years |
| John Baily | M | 80 |
The University of Chicago
| 2 years |
| Wutisak Lapcharoensap | M | 76 |
The University of Chicago
| 1 years |
| Kathleen West | F | - |
The University of Chicago
| 3 years |
| Gordon Hamilton | M | 68 |
The University of Chicago
| 4 years |
| Jose Luiz Alqueres | M | 80 |
The University of Chicago
| 1 years |
| Cheryl Spielman | F | 69 |
The University of Chicago
| 2 years |
| Cheuk Fai Kam | M | 70 |
The University of Chicago
| 2 years |
| Hemant Kamala Jalan | M | 66 |
The University of Chicago
| 2 years |
| Paulo Guedes | M | 73 |
The University of Chicago
| 3 years |
| Thomas H. Hopkins | M | - |
The University of Chicago
| 4 years |
| Stephen R. Daniels | M | - |
The University of Chicago
| 3 years |
| Christopher K. Zarins | M | - |
The University of Chicago
| 15 years |
| Jerry Swiss | M | - |
The University of Chicago
| 1 years |
| Jake Leong Wong | M | 63 |
The University of Chicago
| 4 years |
| Andy R. Stern | M | - |
The University of Chicago
| 3 years |
| Nehme Sabbagh | M | 73 |
The University of Chicago
| 1 years |
| Jay Cohen | M | - |
The University of Chicago
| 3 years |
| A. G. Malliaris | M | - |
The University of Chicago
| 3 years |
| James D. Alt | M | 73 |
The University of Chicago
| 3 years |
| Marcia de Wachter | M | 70 |
The University of Chicago
| 1 years |
| Mark Edward Hunt | M | 63 |
The University of Chicago
| 4 years |
| Mitchell Glass | M | - |
The University of Chicago
| 4 years |
| Mark Alan Abeshouse | M | - |
The University of Chicago
| 2 years |
| David Elliot Eisenbud | M | - |
The University of Chicago
| 1 years |
| David E. Storto | M | - |
The University of Chicago
| 1 years |
| Spencer Lee | M | 68 |
The University of Chicago
| 2 years |
| Mohammad Azab | M | 68 |
Chemokine Therapeutics Corp.
Chemokine Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Chemokine Therapeutics Corp. is a biotechnology company, developing chemokine-based therapies to treat cancer, blood disorders and vascular diseases. The company's product candidates in clinical trials include CTCE-0214, for enhancing the immune system; and CTCE-9908, to prevent the spread of cancer and its continued growth. Chemokine Therapeutics was founded on July 15, 1998 and is headquartered in Vancouver, Canada. | 1 years |
| Michael Kubacki | M | 72 |
The University of Chicago
| 2 years |
| David J. Steirman | M | - |
The University of Chicago
| 2 years |
| Kumar Kirpalani | M | - |
The University of Chicago
| 22 years |
| Harold Jay Levy | M | 70 |
The University of Chicago
| 2 years |
| John Prann | M | 73 |
The University of Chicago
| 2 years |
| Dennis Ward Stattman | M | - |
The University of Chicago
| 2 years |
| Paul Hutchison Saunders | M | - |
The University of Chicago
| 2 years |
| Vicki Avril-Groves | F | 69 |
The University of Chicago
| 3 years |
| Venetia Gerasimou Kontogouri | F | 72 |
The University of Chicago
| 2 years |
| Paul S. Fisher | M | 68 |
The University of Chicago
| 3 years |
| Peter Browning | M | 83 |
The University of Chicago
| 2 years |
| Timothy Hoeksema | M | 77 |
The University of Chicago
| 2 years |
| Richard M. Gunst | M | 68 |
The University of Chicago
| 2 years |
| Marcel Fournier | M | 69 |
The University of Chicago
| 2 years |
| Paul N. Harris | M | 65 |
The University of Chicago
| 4 years |
| John A. Salvette | M | 67 |
The University of Chicago
| 2 years |
| Rick Timmons | M | 72 |
The University of Chicago
| 1 years |
| Daniel P. Reingold | M | - |
The University of Chicago
| 1 years |
| Lourdes Josephine Gotianun-Yap | F | 69 |
The University of Chicago
| 2 years |
| Esther M. Stearns | F | - |
The University of Chicago
| 3 years |
| Peter Brennan | M | 69 |
The University of Chicago
| 2 years |
| Kevin Connelly | M | 71 |
The University of Chicago
| 2 years |
| Jim Koch | M | - |
The University of Chicago
| 3 years |
| Stephen Timothy Kochis | M | - |
The University of Chicago
| 2 years |
| Robert B. Stearns | M | 71 |
The University of Chicago
| 2 years |
| Glenn M. Engelmann | M | - |
The University of Chicago
| 3 years |
| J. Stephen Vanderwoude | M | 80 |
The University of Chicago
| 2 years |
| Marc Bergschneider | M | - |
The University of Chicago
| 2 years |
| Peter M. Bonutti | M | - |
The University of Chicago
| 4 years |
| Jay Nelson Mueller | M | - |
The University of Chicago
| 4 years |
| John J. Studzinski | M | - |
The University of Chicago
| 2 years |
| Glen C. Laschober | M | 70 |
The University of Chicago
| 2 years |
| Cadmus Metcalf Hicks | M | - |
The University of Chicago
| 2 years |
| Peter Wolfgang Hegel | M | - |
The University of Chicago
| 2 years |
| John M. Goense | M | - |
The University of Chicago
| 4 years |
| John E. Brower | M | - |
The University of Chicago
| 4 years |
| Peter Hirsch | M | - |
The University of Chicago
| 4 years |
| Daniel Zaldivar | M | - |
The University of Chicago
| 4 years |
| Gary Byram | M | - |
The University of Chicago
| 5 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 96 | 96.00% |
| Canada | 4 | 4.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- John Osth
- Personal Network
